MOTS-c

weak data

Also seen as: mitochondrial ORF of the 12S rRNA-c

The Dose Guy’s verdict

Sep 1, 2026
4 sources

The most interesting compound on this shelf that nobody has tested in a person. MOTS-c is a mitochondrial peptide with clean mouse data on energy, endurance, and metabolic aging, and zero human dosing data of any kind. I find the mechanism genuinely compelling, especially for holding energy in a deficit or around fasted cardio. But nobody has run an exogenous dosing trial, so the protocol is community lore and the safety is a guess.

Would I take it?Genuinely interesting, genuinely unproven.

What it is

A 16-amino-acid peptide encoded by your own mitochondrial DNA, one of a small family of peptides your mitochondria make and export as signals. MOTS-c activates AMPK, the cell’s energy sensor, through a folate-purine pathway, and under metabolic stress it moves into the nucleus to regulate gene expression directly. Think of it as a distress signal your mitochondria send when energy is tight, telling the rest of the cell to adapt. Endogenous levels shift with age, exercise, and metabolic health, which is how the longevity and biohacker communities found it.

The distinction matters: everything known about MOTS-c in humans is about measuring what your body already makes. Nobody has published a trial of injecting it. The mouse work is where the action results live, and those are genuinely strong for a preclinical compound: performance gains across age groups, metabolic protection, and late-life healthspan extension.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

No human has received exogenous MOTS-c in a published trial. The evidence is mouse efficacy and one in-vitro safety signal worth knowing:

MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance and also prevented diet-induced obesity.Cell Metab 2015 · discovery · mouse

MOTS-c enhanced physical performance in young, middle-aged, and old mice. Treatment begun at 23.5 months increased physical capacity and healthspan.Nat Commun 2021 · mouse aging

The 2019 paper claiming accelerated bone fracture healing was retracted because of inaccuracies while organizing images. If you see MOTS-c marketed for bone repair, that is the source, and it is pulled.Eur Rev 2021 · retraction notice

In adipose-derived stromal cells from six donors with obesity, exogenous MOTS-c reduced proliferation and increased senescence markers p16, p21, and TNF-alpha expression. That is a dish, not a person, but a peptide that can push cells toward senescence deserves attention when no human safety data exists.Inflamm Regen 2026 · in vitro

No controlled human trial testing exogenous MOTS-c administration for efficacy or safety exists.as of Aug 2026

Realistic protocols

No human dose of MOTS-c has been studied, so there is no protocol to defend with data. What the community runs: 5 to 10 mg subcutaneous, two to four times per week, often timed around fasted training or during a cut, because the peptide’s own biology is exercise- and stress-responsive. Those doses are forum consensus, not a study result.

If you run it, go low, go short, and log what you feel. The case for MOTS-c is that the mechanism and the mouse data line up unusually well, not that anyone has proven an exogenous dose does anything in a person. If the energy and endurance shift does not show in the first few weeks, it probably is not coming at that dose.

Side effects

Nobody has measured a side effect of exogenous MOTS-c in a person:

anecdotalInjection-site irritation, reported at standard sub-q volumes.

unknownMOTS-c activates AMPK, the same pathway metformin hits. Whether exogenous doses create blood-sugar effects is unknown and worth checking if you run it fasted.

unknownNo human safety data exists for exogenous MOTS-c. The senescence signal in the adipose cell study above is reason enough to keep courses short and watch closely.